These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30068618)

  • 1. Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark.
    Collin LJ; Cronin-Fenton DP; Ahern TP; Christiansen PM; Damkier P; Ejlertsen B; Hamilton-Dutoit S; Kjærsgaard A; Silliman RA; Sørensen HT; Lash TL
    BMJ Open; 2018 Aug; 8(7):e021805. PubMed ID: 30068618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study.
    Cronin-Fenton DP; Kjærsgaard A; Ahern TP; Mele M; Ewertz M; Hamilton-Dutoit S; Christiansen PM; Ejlertsen B; Sørensen HT; Lash TL; Silliman RA
    Acta Oncol; 2017 Sep; 56(9):1155-1160. PubMed ID: 28585885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
    Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
    Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.
    Hjorth CF; Nielsen AS; Sørensen HT; Lash TL; Damkier P; Hamilton-Dutoit S; Cronin-Fenton D
    Acta Oncol; 2019 Feb; 58(2):168-174. PubMed ID: 30458661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
    Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
    Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients.
    Ahern TP; Collin LJ; Baurley JW; Kjærsgaard A; Nash R; Maliniak ML; Damkier P; Zwick ME; Isett RB; Christiansen PM; Ejlertsen B; Lauridsen KL; Christensen KB; Silliman RA; Sørensen HT; Tramm T; Hamilton-Dutoit S; Lash TL; Cronin-Fenton D
    Cancer Epidemiol Biomarkers Prev; 2020 Mar; 29(3):582-590. PubMed ID: 31932415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study.
    Collin LJ; Maliniak ML; Cronin-Fenton DP; Ahern TP; Christensen KB; Ulrichsen SP; Damkier P; Hamilton-Dutoit S; Yacoub R; Christiansen PM; Sørensen HT; Lash TL
    Breast Cancer Res; 2021 Nov; 23(1):103. PubMed ID: 34736510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
    Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Garne JP; Sørensen HT; Hellberg Y; Christensen M; Pedersen L; Hamilton-Dutoit S
    J Natl Cancer Inst; 2011 Mar; 103(6):489-500. PubMed ID: 21325141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study.
    Cronin-Fenton DP; Hellberg Y; Lauridsen KL; Ahern TP; Garne JP; Rosenberg C; Silliman RA; Sørensen HT; Lash TL; Hamilton-Dutoit S
    Acta Oncol; 2012 Feb; 51(2):254-61. PubMed ID: 22129357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative chemo-endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Nishinihon Cooperative Study Group of Adjuvant Therapy for Breast Cancer.
    Sugimachi K; Maehara Y; Akazawa K; Nomura Y; Eida K; Ogawa M; Konaga E; Tanaka N; Toge T; Dohi K; Noda S; Maeda M; Monden Y
    Breast Cancer Res Treat; 1999 Jul; 56(2):113-24. PubMed ID: 10573104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible deleterious effect of tamoxifen in premenopausal women with locoregional recurrence of breast cancer.
    Borner MM; Bacchi M; Castiglione M
    Eur J Cancer; 1996 Nov; 32A(12):2173-6. PubMed ID: 9014762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial.
    Andersson M; Kamby C; Jensen MB; Mouridsen H; Ejlertsen B; Dombernowsky P; Rose C; Cold S; Overgaard M; Andersen J; Kjaer M
    Eur J Cancer; 1999 Nov; 35(12):1659-66. PubMed ID: 10674010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
    Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
    Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.
    Wilson S; Speers C; Tyldesley S; Chia S; Kennecke H; Ellard S; Lohrisch C
    Clin Breast Cancer; 2016 Aug; 16(4):284-90. PubMed ID: 26705158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.
    Nomura Y; Shirouzu M; Takayama T
    Breast Cancer Res Treat; 1998 May; 49(1):51-60. PubMed ID: 9694611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
    Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
    Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark.
    Hjorth CF; Damkier P; Ejlertsen B; Lash T; Sørensen HT; Cronin-Fenton D
    BMC Med; 2021 Sep; 19(1):235. PubMed ID: 34587961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.